Salesforce completes $25B senior notes offering to fund share repurchase

Salesforce priced a $25.0B senior note offering to fund accelerated share repurchases, its largest-ever note sale, issued across eight tranches with coupons from 4.50% to 6.70% and maturities spanning 2028–2066. Interest accrues from March 13, 2026, with semiannual payments beginning Sept 15, 2026; the unsecured notes rank pari passu with other senior debt, leaving total debt at $17.7B (debt/equity 0.3) against a $177.6B market cap, while the stock trades at $192.80 and FCF yield is ~8%. Truist and Stifel maintain Buy ratings (Truist PT $280, cut from $380; Stifel PT $250, cut from $300), indicating the issuance is shareholder-focused but increases leverage and raises valuation questions.

Analysis

The firm’s decision to accelerate capital returns via incremental unsecured leverage materially shifts the trade-off between near-term EPS optics and longer-term credit optionality. Expect an immediate compression of supply-side float and transient earnings-per-share lift over the next 2–6 quarters, but the real pressure will show up in interest-cost sensitivity and refinancing windows across the 1–7 year horizon.

Second-order winners will be fast-cash-generative software peers with lower leverage (they can outspend on R&D or M&A without credit stigma) and fixed-income desks that can warehouse long-dated IG paper if spreads widen; losers include suppliers to margin-sensitive cloud businesses and any strategic M&A sellers who now face a higher implied buyer cost of capital. The corporate bond curve for software may steepen as a result — creating cheap relative-value entry points in the belly of the curve for patient credit investors.

Key risks: a macro pivot higher in real rates or a growth slow-down would amplify interest expense and could trigger rating agency scrutiny within 3–12 months, reversing equity enthusiasm quickly. Near-term catalysts to watch are quarterly order trends and free cash flow conversion over the next two reporting periods, plus any changes in credit spreads or investor commentary from large IG buyers.

Contrarian angle: the market is over-focusing on EPS accretion and underpricing the probability that incremental leverage will constrain strategic flexibility (M&A, pricing, R&D) if growth falters — meaning upside is conditional, not structural. If management’s growth acceleration narrative slips, expect a fast re-rating: equity downside is asymmetric versus the modest, predictable carry buyers demand from the new paper.

Key Decisions for Investors

• Long CRM equity (or 12-month ATM calls) sized as a directional punt: target +35% in 12 months if order-value trends improve, stop-loss -20% to limit bleed from a credit-led repricing; rationale: capture EPS/accretion re-rate while hedging with tight stops.
• Pair trade — long CRM / short MSFT (equal notional) for 6–12 months: isolates buyback-driven EPS lift vs organic growth leadership; expected alpha 15–25% if capital-return optics outperform product-led execution.
• Credit relative-value — buy short-to-intermediate senior unsecured paper of CRM in the secondary market and hedge duration by shorting matched Treasury exposure (barbell to 2–5yr): earns carry while protecting vs parallel curve moves; unwind on >50bp spread tightening or a downgrade watchlist entry.
• Tail-hedge: purchase 9–12 month CRM puts 15–20% OTM (or buy CDS if accessible) as asymmetric insurance against a rapid credit/earnings shock; cost justified if position sizes are >3% of equity allocation.